
Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary ...
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference Submission based on data from positive GLISTEN phase III trial GSK plc (LSE/NYSE: GSK) today …